Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1953 5
1954 6
1955 13
1956 26
1957 24
1958 29
1959 26
1960 24
1961 30
1962 34
1963 62
1964 89
1965 48
1966 54
1967 47
1968 67
1969 78
1970 80
1971 75
1972 68
1973 82
1974 81
1975 86
1976 63
1977 50
1978 64
1979 54
1980 63
1981 56
1982 55
1983 55
1984 65
1985 69
1986 63
1987 78
1988 85
1989 111
1990 99
1991 114
1992 113
1993 135
1994 116
1995 120
1996 158
1997 116
1998 141
1999 136
2000 154
2001 139
2002 157
2003 184
2004 165
2005 170
2006 165
2007 164
2008 143
2009 152
2010 164
2011 192
2012 185
2013 202
2014 220
2015 245
2016 243
2017 217
2018 241
2019 258
2020 274
2021 254
2022 245
2023 223
2024 92

Text availability

Article attribute

Article type

Publication date

Search Results

7,487 results

Results by year

Filters applied: . Clear all
Page 1
Busulfan.
Buggia I, Locatelli F, Regazzi MB, Zecca M. Buggia I, et al. Ann Pharmacother. 1994 Sep;28(9):1055-62. doi: 10.1177/106002809402800911. Ann Pharmacother. 1994. PMID: 7803883 Review.
Pharmacokinetics of high-dose busulfan are age-dependent. Busulfan systemic exposure and, thus, tissue and tumor exposure are lower in children than with adults. ...At higher dosages, busulfan is a fundamental part of myeloablative therapies for patients unde …
Pharmacokinetics of high-dose busulfan are age-dependent. Busulfan systemic exposure and, thus, tissue and tumor exposure are …
Busulfan.
O'Marcaigh AS, Betcher DL. O'Marcaigh AS, et al. J Pediatr Oncol Nurs. 1996 Jul;13(3):150-2. doi: 10.1177/104345429601300308. J Pediatr Oncol Nurs. 1996. PMID: 8755444 Review. No abstract available.
Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.
Lawson R, Staatz CE, Fraser CJ, Hennig S. Lawson R, et al. Clin Pharmacokinet. 2021 Jan;60(1):17-51. doi: 10.1007/s40262-020-00947-2. Epub 2020 Oct 30. Clin Pharmacokinet. 2021. PMID: 33128207 Review.
One study observed increased sinusoidal obstructive syndrome with maximum busulfan concentration > 1.88 ng/mL. Patient weight, age and GSTA1 genotype are important covariates to consider when individualising busulfan therapy. ...Standardised monitoring of busu
One study observed increased sinusoidal obstructive syndrome with maximum busulfan concentration > 1.88 ng/mL. Patient weight, age …
Myelofibrosis.
Malpas JS. Malpas JS. Proc R Soc Med. 1968 May;61(5):499. Proc R Soc Med. 1968. PMID: 5655243 Free PMC article. No abstract available.
Busulfan in hematopoietic stem cell transplant setting.
McCune JS, Holmberg LA. McCune JS, et al. Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):957-69. doi: 10.1517/17425250903107764. Expert Opin Drug Metab Toxicol. 2009. PMID: 19611402 Review.
Busulfan is commonly used in HCT as it is toxic to the marrow. Busulfan is available as oral or i.v. formulation. The most common significant toxicity of busulfan is sinusoidal obstruction syndrome. Even with the introduction of i.v. busulfan, variabil
Busulfan is commonly used in HCT as it is toxic to the marrow. Busulfan is available as oral or i.v. formulation. The most com
Busulphan lung.
Littler WA, Kay JM, Hasleton PS, Heath D. Littler WA, et al. Thorax. 1969 Nov;24(6):639-55. doi: 10.1136/thx.24.6.639. Thorax. 1969. PMID: 5260190 Free PMC article.
A 61-year-old man with chronic myeloid leukaemia was treated with busulphan (Myleran). After receiving 1 g. of this drug over a period of 20 months he became dyspnoeic and developed crepitations in the lungs. ...Many of these osmiophilic bodies, believed to be the source o …
A 61-year-old man with chronic myeloid leukaemia was treated with busulphan (Myleran). After receiving 1 g. of this drug over a perio …
Treosulphan versus busulphan: pros and cons.
Patel P, Savani B, Byrne M. Patel P, et al. Br J Haematol. 2021 Nov;195(3):304-305. doi: 10.1111/bjh.17816. Epub 2021 Sep 12. Br J Haematol. 2021. PMID: 34514593 No abstract available.
Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).
Vassal G. Vassal G. Anticancer Res. 1994 Nov-Dec;14(6A):2363-70. Anticancer Res. 1994. PMID: 7825973 Review.
High-dose busulfan is used in conditioning regimens before allogeneic or autologous bone marrow transplantation (BMT) in adults and children. ...The definition of a therapeutic window according to the disease and the type of BMT, along with the development of iv-busulfa
High-dose busulfan is used in conditioning regimens before allogeneic or autologous bone marrow transplantation (BMT) in adults and c …
Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, Grunebaum E, Dupuis LL. Zao JH, et al. Biol Blood Marrow Transplant. 2015 Aug;21(8):1471-8. doi: 10.1016/j.bbmt.2015.05.006. Epub 2015 May 11. Biol Blood Marrow Transplant. 2015. PMID: 25977229 Free article.
Busulfan AUCs were calculated for each patient based on plasma busulfan concentrations using either a 1-compartment model or a validated limited-sampling strategy. Published pediatric busulfan dosing guidelines were identified. Initial busulfan doses w
Busulfan AUCs were calculated for each patient based on plasma busulfan concentrations using either a 1-compartment model or a
11C-labeling of busulphan.
Hassan M, Thorell JO, Warne N, Stone-Elander S. Hassan M, et al. Int J Rad Appl Instrum A. 1991;42(11):1055-9. doi: 10.1016/0883-2889(91)90010-x. Int J Rad Appl Instrum A. 1991. PMID: 1667312
Dimesylation of the diol with methanesulfonyl chloride in dichloromethane/pyridine yielded [1-11C]busulphan with conversions in the order of 30-35%. The total time of synthesis, including HPLC purification, was 65-75 min from the end-of-trapping of [11C]ammonium cyanide. T …
Dimesylation of the diol with methanesulfonyl chloride in dichloromethane/pyridine yielded [1-11C]busulphan with conversions in the o …
7,487 results